Cannell & Co. Erytech Pharma S.A. Transaction History

Cannell & Co.

  • $3.01 Billion
  • Q4 2023

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 09, 2022
SELL
$2.15 - $6.21 $55,900 - $161,460
-26,000 Closed
0 $0
Q3 2021

Nov 10, 2021
BUY
$4.11 - $6.47 $106,860 - $168,220
26,000 New
26,000 $150,000

About Erytech Pharma S.A.

ERYP Quotes by TradingView
  • Ticker ERYP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,018,600
  • Market Cap $16.8M
  • Description
  • ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of...
More about ERYP
Track This Portfolio

Track Cannell & Co. Portfolio

Follow Cannell & Co. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cannell & Co., based on Form 13F filings with the SEC.

News

Stay updated on Cannell & Co. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email